New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...

Other analysts are more cautious, however, predicting peaks sales of $1 billion or lower and pointing to lacklustre take-up of other new obesity drugs such as Eisai and Arena's Belviq (lorcaserin ...

The past year has seen the rise of myriad weight-loss drugs that are getting ... In America, the trend of increasing obesity has stalled and even slightly reversed. In 2021-2023, 40 per cent ...

LONDON, Dec 18 (Reuters) - A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end to the obesity pandemic” alongside other interventions ...

One option is to double down on the obesity market, by buying promising new drugs that may complement or even replace the GLP-1 products. One target could be Zealand Pharma (ZELA.CO), opens new ...

(Those are slightly higher shares than the estimate from the Center s for Disease Control and Prevention, which says around 40% of U.S. adults had obesity from 2021 ... the new drugs' true impact.

in New York City. Gary Hershorn/Getty Images Last year, poison control centers across the country reported spikes in calls related to overdoses of anti-obesity medications. Authorities attributed ...

U.S. obesity declined slightly in 2023, new data showed, perhaps marking the first time in over a decade there’s been a decline. The dip comes amid the booming popularity of weight loss drugs ...

LONDON – A new class of weight-loss drugs developed by pharmaceutical companies Novo Nordisk and Eli Lilly “opens the possibility of an end to the obesity pandemic” alongside other ...